Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza Hemagglutinin mRNA vaccine · 1 trial · 2 indications
Number of participants with unsolicited systemic immediate adverse events (AEs)
Number of participants with solicited injection site reactions
Number of participants with solicited systemic reactions
Number of participants with unsolicited AEs
Number of participants with medically attended adverse events (MAAE)s
Number of participants with serious adverse events (SAEs)
Number of participants with out-of-range biological test results
| Arm | Type | Description |
|---|---|---|
| sentinel cohort 1 | EXPERIMENTAL | 20 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 1 or dose 2 and half number of the participants in each age group also receiving the RIV4 control |
| sentinel cohort 2 | EXPERIMENTAL | 20 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 3 or dose 4 and half number of the participants in each age group also receiving the RIV4 control |
| sentinel cohort 3 | EXPERIMENTAL | 10 Participants in each age group will receive Influenza hemagglutinin mRNA vaccine candidate dose 5 with half of the participants in each age group also receiving the RIV4 control |
| main cohort 1 | EXPERIMENTAL | 40 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 1 or dose 2 and half number of the participants in each age group also receiving the RIV4 control |
| main cohort 2 | EXPERIMENTAL | 40 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 3 or dose 4 and half number of the participants in each age group also receiving the RIV4 control |
| main cohort 3 | EXPERIMENTAL | 20 Participants in each age group will receive Influenza hemagglutinin mRNA vaccine candidate dose 5, and half number of the participants in each age group also receiving the RIV4 control |
| Name | Type | Description |
|---|---|---|
| Influenza Hemagglutinin mRNA vaccine | BIOLOGICAL | Pharmaceutical form:Solution for injection-Route of administration:IM injection |
| Quadrivalent Recombinant Influenza Vaccine | BIOLOGICAL | Pharmaceutical form:Solution for injection-Route of administration:IM injection |
Inclusion Criteria: * Having given written informed consent prior to undertaking any study-related procedure. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: * Any subject who, in the judgment of the Investigator, is likely to be noncompliant dur...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
The Influenza Hemagglutinin mRNA vaccine is an investigational vaccine developed by Sanofi for the prevention of influenza. It uses mRNA to encode influenza hemagglutinin, the viral protein that the immune system recognizes. It is in Phase 1 clinical development and is not approved for use.
The Influenza Hemagglutinin mRNA vaccine is being developed for influenza immunization, meaning prevention of influenza infection. It is an investigational vaccine in Phase 1 testing and has not been approved for any indication.
The Influenza Hemagglutinin mRNA vaccine is developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor of the clinical program evaluating this mRNA-based influenza vaccine candidate.
The Influenza Hemagglutinin mRNA vaccine is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by the FDA or any other regulatory agency.
The Influenza Hemagglutinin mRNA vaccine has been studied in one Phase 1 trial, NCT06118151, titled Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older. The trial enrolled 388 participants in the United States and is completed.
The Phase 1 trial NCT06118151 was a randomized, double-blind, controlled study of the monovalent mRNA vaccine encoding influenza hemagglutinin. It enrolled 388 adults aged 18 years and older, including healthy volunteers, and was conducted in the United States. The trial is completed.